ONTX Key Statistics, Chart & Performance
The current stock price of ONTX is 0.9953 USD. In the past month the price increased by 7.02%. In the past year, price increased by 42.19%.
ONTX Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to ONTX. When comparing the yearly performance of all stocks, ONTX is one of the better performing stocks in the market, outperforming 91.64% of all stocks.
ONTX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ONTX. The financial health of ONTX is average, but there are quite some concerns on its profitability.
ONTX Financial Highlights
Over the last trailing twelve months ONTX reported a non-GAAP Earnings per Share(EPS) of -0.97. The EPS decreased by -21.25% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -74.67% | ||
| ROE | -139.07% | ||
| Debt/Equity | 0 |
ONTX Forecast & Estimates
9 analysts have analysed ONTX and the average price target is 8.5 USD. This implies a price increase of 754.01% is expected in the next year compared to the current price of 0.9953.
For the next year, analysts expect an EPS growth of -7.23% and a revenue growth 2.54% for ONTX
ONTX Ownership
ONTX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 31.12 | 1T | ||
| JNJ | JOHNSON & JOHNSON | 20.48 | 578.208B | ||
| MRK | MERCK & CO. INC. | 21.74 | 302.633B | ||
| PFE | PFIZER INC | 9.01 | 154.765B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.99 | 126.196B | ||
| ZTS | ZOETIS INC | 18.54 | 56.153B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.49 | 25.774B | ||
| VTRS | VIATRIS INC | 6.15 | 16.793B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.75 | 12.521B | ||
| AXSM | AXSOME THERAPEUTICS INC | 223.72 | 9.202B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ONTX
Company Profile
Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification and development of oncology therapeutics. The company is headquartered in Newtown, Pennsylvania and currently employs 16 full-time employees. The company went IPO on 2013-07-25. The company has molecularly targeted agents designed to disrupt specific cellular pathways for cancer cell proliferation. The company has the two clinical-stage programs: narazaciclib (ON 123300), which is a multi-targeted kinase inhibitor in solid tumors and hematological malignancies as a single agent or in combination with other anti-cancer therapies; and rigosertib administered alone or in combination for the treatment of solid tumors. Narazaciclib targets cyclin-dependent kinases (CDK's), AMPK related protein kinase 5 (ARK5), and colony-stimulating factor 1 receptor (CSF1R) at low nM concentrations as well as other tyrosine kinases. The company is also engaged in supporting investigator-initiated studies (IIS) that explores the use of rigosertib for cancers driven by mutated K-Ras genes, including a Phase I/IIa study of rigosertib with a PD-1 inhibitor.
Company Info
ONCONOVA THERAPEUTICS INC
375 Pheasant Run
Newtown PENNSYLVANIA 18940 US
CEO: Steven M. Fruchtman
Employees: 16
Phone: 12677593681
ONCONOVA THERAPEUTICS INC / ONTX FAQ
Can you describe the business of ONCONOVA THERAPEUTICS INC?
Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification and development of oncology therapeutics. The company is headquartered in Newtown, Pennsylvania and currently employs 16 full-time employees. The company went IPO on 2013-07-25. The company has molecularly targeted agents designed to disrupt specific cellular pathways for cancer cell proliferation. The company has the two clinical-stage programs: narazaciclib (ON 123300), which is a multi-targeted kinase inhibitor in solid tumors and hematological malignancies as a single agent or in combination with other anti-cancer therapies; and rigosertib administered alone or in combination for the treatment of solid tumors. Narazaciclib targets cyclin-dependent kinases (CDK's), AMPK related protein kinase 5 (ARK5), and colony-stimulating factor 1 receptor (CSF1R) at low nM concentrations as well as other tyrosine kinases. The company is also engaged in supporting investigator-initiated studies (IIS) that explores the use of rigosertib for cancers driven by mutated K-Ras genes, including a Phase I/IIa study of rigosertib with a PD-1 inhibitor.
What is the current price of ONTX stock?
The current stock price of ONTX is 0.9953 USD. The price decreased by -0.47% in the last trading session.
Does ONCONOVA THERAPEUTICS INC pay dividends?
ONTX does not pay a dividend.
How is the ChartMill rating for ONCONOVA THERAPEUTICS INC?
ONTX has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is ONCONOVA THERAPEUTICS INC worth?
ONCONOVA THERAPEUTICS INC (ONTX) has a market capitalization of 20.90M USD. This makes ONTX a Nano Cap stock.